Updates are available Correction dated 2025-02-25
Click to view Correction: https://doi.org/10.1038/s41556-025-01643-8
-
Authors
MacDonald, Ewan
Forrester, Alison https://orcid.org/0000-0003-3352-9173
Valades-Cruz, Cesar A. https://orcid.org/0000-0002-1786-8207
Madsen, Thomas D.
Hetmanski, Joseph H. R.
Dransart, Estelle
Ng, Yeap
Godbole, Rashmi
Shp, Ananthan Akhil
Leconte, Ludovic
Chambon, Valérie
Ghosh, Debarpan
Pinet, Alexis
Bhatia, Dhiraj https://orcid.org/0000-0002-1478-6417
Lombard, Bérangère https://orcid.org/0000-0001-9044-3662
Loew, Damarys https://orcid.org/0000-0002-9111-8842
Larsen, Martin R. https://orcid.org/0000-0001-6203-0123
Leffler, Hakon https://orcid.org/0000-0003-4482-8945
Lefeber, Dirk J.
Clausen, Henrik https://orcid.org/0000-0002-0915-5055
Blangy, Anne https://orcid.org/0000-0001-7043-0784
Caswell, Patrick https://orcid.org/0000-0002-2633-2324
Shafaq-Zadah, Massiullah https://orcid.org/0000-0002-7582-8131
Mayor, Satyajit https://orcid.org/0000-0001-9842-6963
Weigert, Roberto https://orcid.org/0000-0003-0740-4465
Wunder, Christian https://orcid.org/0000-0001-9091-0080
Johannes, Ludger https://orcid.org/0000-0002-2168-0004
- License Information
-
More Information
Article History
Received: 2 January 2024
Accepted: 9 January 2025
First Online: 21 February 2025
Change Date: 25 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41556-025-01643-8
Competing interests
: H.L. is a shareholder in Galecto Biotech AB, a company that is developing galectin inhibitors. The other authors declare no conflicts of interest.
